Braydan Uses, Dosage, Side Effects and more
Braydan is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery in adults. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Braydan provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Braydan (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
| Attribute | Details |
|---|---|
| Trade Name | Braydan |
| Availability | Prescription only |
| Generic | Sugammadex |
| Sugammadex Other Names | Sugammadex |
| Related Drugs | pyridostigmine, neostigmine, Mestinon, Bridion, edrophonium, Bloxiverz |
| Type | |
| Formula | C72H112O48S8 |
| Weight | Average: 2002.12 Monoisotopic: 2000.408874758 |
| Protein binding | Sugammadex does not bind plasma proteins. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Russia |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Braydan is a modified gamma cyclodextrin used to reverse neuromuscular blockade induced by vecuronium bromide and rocuronium bromide which are agents used for anesthesia.
Braydan is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.
Braydan is also used to associated treatment for these conditions: Neuromuscular blockade caused by vecuronium bromide
How Braydan works
Braydan is a modified gamma-cyclodextrin which forms very tight water soluble complexes at a 1:1 ratio with steroidal neuromuscular blocking drugs (rocuronium > vecuronium >> pancuronium). Braydan creates a concentration gradient which favors movement of rocurionium from the neuromuscular junction into the plasma, which quickly reverses rocuronium-induced neuromuscular blockade. The free rocuronium in the plasma are then bound tightly to sugammadex, assisting the diffusion of the remaining rocuronium molecules out of the neuromuscular junction and increasing bound and free rocuronium in the plasma.
Toxicity
Patients with severe renal impairment (with creatinine clearance below 30 mL/min) should avoid use of drug as their clearance of the drug is reduced and there is inconsistent evidence about its safety in this subset of patients.
Food Interaction
No interactions found.Drug Interaction
Moderate: heparinUnknown: aspirin, charcoal, epinephrine, albendazole, RHO Immunoglobulin , calcium / vitamin d, calcium / vitamin d, multivitamin, lithium, metoprolol, acetaminophen, procaine penicillin, penicillin v potassium, phenytoin, vitamin a topical, bioflavonoids, sotalol, valproic acid, cholecalciferol
Disease Interaction
Moderate: bleeding, liver dysfunction, renal impairment
Volume of Distribution
At steady state, the volume of distribution is 11-14 L in adult patients with normal renal function.
Elimination Route
Braydan is administered intravenously.
Half Life
About 2 hours
Clearance
88L/min
Elimination Route
Renal excretion of unchanged product. >90 of dose is excreted within 24 hours. 0.02% is excreted in feces and air.
